Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 56

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 56
---
 incorporated herein by reference.

Warrants

The following summary
of certain terms and provisions of the Warrants accompanying the shares of common stock and the Pre-Funded Warrants that are
being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrants, the form of which
is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review
the terms and provisions of the form of Warrant for a complete description of the terms and conditions of the Warrants. The Series A-1
Warrant and Series A-2 Warrant are identical except with regard to their duration.

Duration and Exercise Price

Each Warrant offered
hereby will have an exercise price of $ per share and will be exercisable beginning on the effective
date of the Warrant Stockholder Approval, provided, however, if the Pricing Conditions are met, the Warrants will be exercisable upon
issuance (the “Initial Exercise Date”). The exercise price and number of shares of common stock issuable upon exercise of
the warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting
our common stock and the exercise price. The Warrants will be issued separately from the common stock and Pre-Funded Warrants and may
be transferred separately immediately thereafter. The Warrants will be issued in certificated form only. The Series A-1 Warrants will
expire on the anniversary of the Initial Exercise Date. The Series A-2 Warrants will expire on the anniversary of the Initial Exercise
Date.

We intend to promptly,
and in no event later than 90 days after the consummation of this offering, seek stockholder approval for the issuance of shares of common
stock issuable upon exercise of the Warrants but we cannot assure you that such stockholder approval will be obtained, provided, however,
that, if and only if the Pricing Conditions are satisfied, then we will not seek Warrant Stockholder Approval. We have agreed with the
investors in this offering that, if we do not obtain stockholder approval for the issuance of the shares of common stock upon exercise
of the Warrants at the first stockholder meeting for such purpose after this offering, we will call a stockholder meeting every 90 days
thereafter until the earlier of the date we obtain such approval or the Warrants are no longer outstanding, provided, however, that, if
and